GB Sciences Puts Its Grey Matter To Work Solving The Big Green Riddle
Quality and consistency of raw materials to research, manufacture and deliver trusted medical-cannabis formulations has been the single largest stumbling block for cannabis-based medical formulations to become mainstream. The stage is now set for this to become a reality thanks to four years of intensive research and development by GB Sciences.
LAS VEGAS, May 23, 2018/GLOBE NEWSWIRE/–. GB Sciences, Inc. (OTCQB: GBLX)
For large scale adoption of Cannabis in medical formulations the quality, consistency and trust in the raw ingredients is essential in providing a true scientific base line and prove efficacy in the medical world. To date, no one has been able to solve this all-important riddle…Until now.
John Poss, Chairman and CEO of GB Sciences explained; “We have been quietly building a formidable cannabis research and development program for the past four years with the aim of solving the big riddle. We knew that unlocking the properties of the plant and standardizing those properties in a manner that could be reliably replicated was the key to getting cannabis past the current phase of purely anecdotal evidence and prove its true value as a medicine for all patients.” Mr. Poss continued, “The GB Sciences philosophy required assembling a dedicated and disparate team with a singleminded focus on science. This team is perhaps our most noteworthy achievement, and their dogged dedication to a single goal has now paid off on all fronts. We are now ready to make evidence-based botanical medicines and nutraceuticals from cannabis a reality.”
Control of two elements is necessary to produce consistent raw ingredients for medical-cannabis products… the original genetics and the growing environments. Tissue culture propagation supplies the answer to the first part of the riddle and precision controlled growing environments provide the answer to the second part.
“At GB Sciences we have pioneered tissue culture propagation as one important tool for achieving consistency in the genetics we produce”, said Dr. Ulrich Reimann-Philipp, Chief Botanist at GB Sciences. “This technique allows us to produce healthy, genetically identical copies of prime mother plants resulting in optimal cannabinoid and terpene profiles over multiple grow cycles. Tissue culture is also essential for developing novel methods to preserve and improve genetic assets, for example through cryo-preservation.”
The GB Sciences facility in Las Vegas is a true showplace for the cannabis industry. Unique and innovative in all aspects of cultivation and production it is now producing some of the most highly sought after adult use products in the Nevada market. Besides being the base platform to prove the theory of a consistent and trusted brand, the revenue has been used to fund the hypothesis that being dedicated to scientific proof pays large dividends in the long run.
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.